ComboMATCH Treatment Trials to Test New Drug Combinations Guided By Tumor Biology

The National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) is a large precision medicine initiative with a coordinated set of clinical trials evaluating new anti-cancer drug combinations in select groups of adults and children with cancer. Each trial is geared to studying the effectiveness of a specific drug combination in a select group of patients. The drug combinations are either two targeted therapies or chemother


2024 Fall Hybrid Group Meeting
- October 30-November 1

2025 Spring Hybrid Group Meeting
- April 30-May 3

All meetings are open to all
Alliance members.